The Marriage of Small Molecules and Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Marriage of Small Molecules and Biologics
Approaches in using small-molecule and peptide synthesis offer promise in widening the scope of drug candidates.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 56-60

Other approaches

Improving peptide synthesis also is an area of ongoing research. Researchers from Vanderbilt University recently reported their efforts in overcoming a limitation in peptide synthesis, the incorporation of non-natural amino acids into the peptide chain. The researchers noted that creation of amide bonds typically use methods that principally are based on dehydrative approaches or oxidative and radical-based methods. Generally, carbon and nitrogen bear electrophilic and nucleophilic character, respectively, during the carbon–nitrogen bond-forming step. In their work, the researchers showed the activation of amines and nitroalkanes with an electrophilic iodine source to directly make amide products. The suggested mechanism showed that the polarities of the two reactants were reversed during carbon–nitrogen bond formation relative to traditional approaches. Looking forward, the researchers noted that using nitroalkanes as acyl anion equivalents provides a conceptually innovative approach to amide and peptide synthesis, and one that may further engender more efficient peptide synthesis that relies on enantioselective methods (7).

"Scientists from many disciplines have sought improved methods to streamline the synthesis of peptides through purely chemical means in order to increase the diversity of the chemical tools available for the design of improved therapeutics," said Jeff Johnston, professor of chemistry at Vanderbilt University, in a June 23, 2010, Vanderbilt University press release. "Our discovery of a conceptually new approach to peptide synthesis brings this capability much closer to reality."

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
.

References

1. T. Sawyer, Chem. Biol. Drug. Des. 73 (1), 3–6 (2009).

2. W. Wolfson, Chem. & Biol. 16 (9), 910–911 (2009).

3. J.B. Binder and R. Raines, Curr. Opin. Chem. Biol. 12 (6), 767–773 (2008).

4. H.E. Blackwell and R. Grubbs, Angew. Chem. Int. Ed. 37, 3281–3284 (1998).

5. G.H. Bird et al., Proc. Natl. Acad. Sci., DOI/10.1073pnas.1002713107 (June 18, 2010).

6. Q. Lin et al., Biorg. Med. Chem. Lett. 21 (5) 1472–1475 (2011).

7. B. Shen, D. Makely, and J.N. Johnston., Nature 465 (7301), 1027–1032 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here